

## ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

### SUMMARY

#### OFFER PRICE

The Offer Price has been determined at HK\$20.15 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

#### Net Proceeds from the Global Offering

Based on the Offer Price of HK\$20.15 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees, commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised, is estimated to be approximately HK\$1,747.5 million (assuming the Over-allotment Option is not exercised). The Company intends to apply such net proceeds in accordance with the purposes as set out in the section headed “Net Proceeds from the Global Offering” in this announcement.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$270.7 million for 13,852,000 additional Offer Shares to be sold and transferred upon the exercise of the Over-allotment Option.

#### Applications under the Hong Kong Public Offering

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been very significantly over-subscribed. A total of 194,271 valid applications have been received pursuant to the Hong Kong Public Offering on **WHITE** and **YELLOW** Application Forms and through giving **electronic application instructions** to HKSCC via CCASS and under the **White Form eIPO** service ([www.eipo.com.hk](http://www.eipo.com.hk)) for a total of 5,091,437,500 Hong Kong Offer Shares, representing approximately 551.32 times the total number of 9,235,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering. The total number of successful applicants under the Hong Kong Public Offering is 44,242.

As the over-subscription in the Hong Kong Public Offering is more than 100 times, the reallocation procedures as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus have been applied. A total number of 36,939,000 Offer Shares have been reallocated to the Hong Kong Public Offering from the International Offering. As a result of such reallocation, the final number of Offer Shares available under the Hong Kong Public Offering has been increased to 46,174,000 Offer Shares, representing approximately 50% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

## **International Offering**

The Offer Shares initially offered under the International Offering have been significantly over-subscribed, which, based on orders received from the International Underwriters, represents more than 8 times the total number of Offer Shares initially available under the International Offering. Taking into account the reallocation of 36,939,000 Offer Shares from the International Offering to the Hong Kong Public Offering, the final number of Offer Shares under the International Offering is 46,173,500 Shares, representing approximately 50% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 13,852,000 Offer Shares under the International Offering. A total number of 175 places have been allocated Offer Shares under the International Offering.

## **Cornerstone Investors**

Based on the Offer Price of HK\$20.15 per Offer Share, pursuant to the cornerstone investment agreements, the Cornerstone Investors have subscribed for a total of 44,235,000 Offer Shares, representing in aggregate (a) approximately 11.98% of the issued share capital of the Company immediately upon completion of the Global Offering and (b) approximately 47.90% of the number of Offer Shares under the Global Offering, in each case assuming the Over-allotment Option is not exercised. Please refer to the section headed “Cornerstone Investors” in the Prospectus for further details of the Cornerstone Investors.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver from strict compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 5(2) of Appendix 6 to the Listing Rules (the “**Placing Guidelines**”), to permit (i) Highlight Medical Limited and (ii) Cherry Cheeks HK Limited (each an existing shareholder of the Company) to subscribe for Offer Shares as Cornerstone Investors in the Global Offering. Please refer to the section headed “Waivers from Compliance with the Listing Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus.

## **Placing of Offer Shares with consent under the Placing Guidelines**

Under the International Offering, 155,000, 25,000 and 400,000 Offer Shares, representing approximately 0.17%, 0.03% and 0.43% of the Offer Shares initially available under the Global Offering (before the exercise of the Over-allotment Option), were respectively placed to CSOP Asset Management Limited (“**CSOP**”) and Huatai Capital Investment Limited (“**Huatai Capital**”) and UBS Asset Management (Singapore) Limited (“**UBS AM (Singapore)**”), all being connected clients of certain Underwriters of the Global Offering within the meaning of the Placing Guidelines, as placees.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted us, consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to CSOP, Huatai Capital and UBS AM (Singapore) as placees. The Offer Shares placed to the connected clients are held by the respective connected clients on behalf of independent third parties and are in compliance with all the conditions under the consent granted by the Stock Exchange.

Save as disclosed in the paragraphs headed “Cornerstone Investors” and “Placing of Offer Shares with consent under the Placing Guidelines” in this announcement, and pursuant to the cornerstone investment agreements, no Offer Shares placed by or through the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers and the Underwriters under the Global Offering have been placed with any core connected person (as defined in the Listing Rules) of the Company or any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees. The Directors confirm that save for Zhuhai Gree Financial Investment Management Co. Ltd, no placee, individually, will hold more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering (assuming the Over-allotment Option is not exercised).

The Directors confirm that, to the best of their knowledge, (a) save for Zhuhai Gree Financial Investment Management Co. Ltd, there will not be any new substantial Shareholder immediately after the Global Offering and (b) save as the Cornerstone Investors which are existing Shareholders, namely, Highlight Medical Limited and Cherry Cheeks HK Limited (please refer to the paragraph headed “Cornerstone Investors”), none of the Offer Shares subscribed by the placees and the public has been financed directly or indirectly by any of the Directors, chief executives of the Company, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates, and none of the placees or the public who have subscribed for the Offer Shares is accustomed to taking instructions from any of the Directors, chief executives of the Company, the substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in his/her/its name or otherwise held by him/her/it.

## Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators on behalf of the International Underwriters, at any time from the Listing Date until Sunday, 14 June 2020, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to an aggregate of 13,852,000 additional Offer Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any. There has been an over-allocation of 13,852,000 Shares in the International Offering which will be from Shares to be borrowed under the Stock Borrowing Agreement between KT International and the Stabilising Manager. Such borrowed Shares will be covered by (i) exercising the Over-allotment Option in full or in part, (ii) by making purchases by the Stabilising Manager (or any person acting for it) in the secondary market at prices that do not exceed the Offer Price, or (iii) by a combination of these means. If the Over-allotment Option is exercised, an announcement will be made in accordance with the Listing Rules. As at the date of this announcement, the Over-allotment Option has not been exercised.

## LOCK-UP UNDERTAKINGS

The Company, the Controlling Shareholders, the existing Shareholders (comprising KT International, KG Development and the Pre-IPO investors) and the Cornerstone Investors are subject to certain lock-up undertakings as set out in the paragraph headed “Lock-up Undertakings” in this announcement.

## RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for under **WHITE** and **YELLOW** Application Forms and by giving **electronic application instructions** to HKSCC or through the designated **White Form eIPO** service, including the Hong Kong identity card numbers, passport numbers or Hong Kong business registration numbers of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:

- in this announcement posted on the Company’s website at [www.kintor.com.cn](http://www.kintor.com.cn) and the Stock Exchange’s website at [www.hkexnews.hk](http://www.hkexnews.hk) by no later than 9:00 a.m. on Thursday, 21 May 2020;
- from the designated results of allocations website at [www.iporeresults.com.hk](http://www.iporeresults.com.hk) (alternatively: English <http://www.eipo.com.hk/en/Allotment>; Chinese <http://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID” function on a 24-hour basis from 8:00 a.m. on Thursday, 21 May 2020 to 12:00 midnight on Wednesday, 27 May 2020;
- by telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. from Thursday, 21 May 2020 to Friday, 22 May 2020 and from Monday, 25 May 2020 to Tuesday, 26 May 2020;
- in the special allocation results booklets which will be available for inspection during opening hours from Thursday, 21 May 2020 to Monday, 25 May 2020 at all the designated branches of the receiving banks.

Results of allocations of the Hong Kong Offer Shares in the Hong Kong Public Offering, the level of indication of interests in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will also be published on Thursday, 21 May 2020 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese) (the “**Newspapers**”) and on the Company’s website at [www.kintor.com.cn](http://www.kintor.com.cn) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

### **Despatch/Collection of Share Certificates and Refund Monies**

Applicants who apply for 1,000,000 or more Hong Kong Offer Shares and have provided all information required by their **WHITE** Application Forms and applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the **White Form eIPO** service by submitting an electronic application through the designated website [www.eipo.com.hk](http://www.eipo.com.hk) and their application is wholly or partially successful, may collect their refund check(s) and/or share certificate(s) from Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, 21 May 2020, or such other date as notified by the Company in the Newspapers. If such applicants do not collect their refund check(s) and/or share certificate(s) personally within the time specified for collection, they will be despatched promptly to the address specified in their Application Forms by ordinary post at their own risk.

Applicants who have applied for less than 1,000,000 Hong Kong Offer Shares and have provided all information required by their **WHITE** Application Forms and applicants who have applied for less than 1,000,000 Hong Kong Offer Shares through the **White Form eIPO** service by submitting an electronic application through the designated website [www.eipo.com.hk](http://www.eipo.com.hk) and their application is wholly or partially successful, will have their refund check(s) and/or share certificate(s) sent to their address on the relevant Application Forms on or before Thursday, 21 May 2020, by ordinary post and at their own risk. For applicants using the **White Form eIPO** service and who have paid the application monies from a single bank account, any refund monies will be dispatched to that bank account in the form of e-Refund payment instructions. For applicants using the **White Form eIPO** service and who have paid the application monies from multiple bank accounts, any refund monies will be dispatched to the address as specified in their application instructions in the form of refund check(s) by ordinary post at their own risk.

Wholly or partially successful applicants using a **YELLOW** Application Form or who gave **electronic application instructions** to HKSCC will have their share certificate(s) issued in the name of HKSCC Nominees and deposited into CCASS for credit to their designated CCASS Participant’s stock account or their CCASS Investor Participant stock account as stated in their applications on Thursday, 21 May 2020, or, on any other date determined by HKSCC or HKSCC Nominees.

Wholly or partially unsuccessful applicants who have applied for 1,000,000 or more Hong Kong Offer Shares under **YELLOW** Application Forms may collect their refund check(s) from the Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, 21 May 2020, or such other date as notified by the Company in the Newspapers. If such applicants do not collect their refund check(s) personally within the time specified for collection, they will be despatched promptly to the address specified in their Application Forms by ordinary post at their own risk.

Wholly or partially unsuccessful applicants who have applied for less than 1,000,000 Hong Kong Offer Shares under **YELLOW** Application Forms will have their refund check(s) sent to the address on the relevant Application Forms on or before Thursday, 21 May 2020, by ordinary post and at their own risk.

Refund of application monies in respect of wholly or partially unsuccessful applications who gave **electronic application instructions** to HKSCC will be credited to their designated bank account or the designated bank account of their broker or custodian on Thursday, 21 May 2020.

### **Public Float**

The Directors confirm that the number of Offer Shares in public hands and the market capitalization of the number of shares to be held by the public will satisfy the minimum requirement prescribed under Rule 8.08(1) and Rule 18A.07 of the Listing Rules. The Directors confirm that the three largest public Shareholders do not hold more than 50% of the shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules. The Directors confirm that there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

### **Commencement of Dealings in the Shares**

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. Share certificates for the Offer Shares will only become valid certificates of title at 8:00 a.m. in Hong Kong on Friday, 22 May 2020, provided that (i) the Global Offering has become unconditional in all respects and (ii) the right of termination as described in the section headed "Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Hong Kong Underwriting Agreement – Grounds for Termination" in the Prospectus has not been exercised.

Assuming that the Global Offering becomes unconditional in all aspects at 8:00 a.m. in Hong Kong on Friday, 22 May 2020, dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. in Hong Kong on Friday, 22 May 2020. The Shares will be traded in board lots of 500 Shares each under the Company's stock code 9939.



## OFFER PRICE

The Offer Price has been determined at HK\$20.15 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

## NET PROCEEDS FROM THE GLOBAL OFFERING

Based on the Offer Price of HK\$20.15 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees, commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised, is estimated to be approximately HK\$1,747.5 million. The Company intends to apply the proceeds from the Global Offering as follows:

- approximately 42% of the net proceeds (approximately HK\$734.0 million) allocated to the development and commercialisation of one of our Core Products, Proxalutamide, as follows:
  - o clinical trials: approximately 20% of the net proceeds (approximately HK\$349.5 million) will be allocated to the ongoing and planned clinical trials for Proxalutamide in China and approximately 7% of the net proceeds (approximately HK\$122.3 million) will be allocated to the ongoing and planned clinical trials for Proxalutamide in the United States;
  - o manufacturing: approximately 9% of the net proceeds (approximately HK\$157.3 million) will be allocated to the construction of GMP-compliant production line in preparation for the commercialisation of Proxalutamide;
  - o sales and marketing: approximately 6% of the net proceeds (approximately HK\$104.9 million) will be allocated to the preparation for commercialisation of Proxalutamide. We plan to bring on board a full sales and marketing team consisting of over 100 personnel for the sales and marketing of Proxalutamide in China;
- approximately 28% of the net proceeds (approximately HK\$489.3 million) allocated to the development and commercialisation of one of our Core Products, Ppyrilutamide, as follows:
  - o clinical trials: approximately 6% of the net proceeds (approximately HK\$104.9 million) will be allocated to the ongoing and planned clinical trials for Ppyrilutamide in China and approximately 7% of the net proceeds (approximately HK\$122.3 million) will be allocated to the ongoing and planned clinical trials for Ppyrilutamide in the United States;
  - o manufacturing: approximately 8% of the net proceeds (approximately HK\$139.8 million) will be allocated to the construction of GMP-compliant production line in preparation for the commercialisation of Ppyrilutamide. Please refer to the section headed “Business – Commercialisation” for further details;
  - o sales and marketing: approximately 7% of the net proceeds (approximately HK\$122.3 million) will be allocated to establishing the sales and marketing infrastructure for Ppyrilutamide;

- approximately 4% of the net proceeds (approximately HK\$69.9 million) allocated to the development for our clinical stage drug candidate ALK-1:
  - o clinical trials: approximately 3% of the net proceeds (approximately HK\$52.4 million) will be allocated to the clinical trials of ALK-1 in China;
  - o manufacturing: approximately 1% of the net proceeds (approximately HK\$17.5 million) will be allocated to the application for clinical trials registration and the manufacture of ALK-1 in China;
- approximately 4% of the net proceeds (approximately HK\$69.9 million) allocated to the development for our clinical stage drug candidate Detorsertib:
  - o clinical trials: approximately 0.5% of the net proceeds (approximately HK\$8.7 million) will be allocated to the clinical trials of Detorsertib in China;
  - o manufacturing: approximately 3.5% of the net proceeds (approximately HK\$61.2 million) will be allocated to the manufacture of Detorsertib in China;
- approximately 4% of the net proceeds (approximately HK\$69.9 million) allocated to the development of our clinical stage drug candidate GT1708F (Hedgehog/SMO Inhibitor):
  - o clinical trials: approximately 0.5% of the net proceeds (approximately HK\$8.7 million) will be allocated to the clinical trials of GT1708F in China;
  - o manufacturing: approximately 3.5% of the net proceeds (approximately HK\$61.2 million) will be allocated to the manufacture of GT1708F in China;
- approximately 2% of the net proceeds (approximately HK\$35.0 million) allocated to other clinical study projects;
- approximately 6% of the net proceeds (approximately HK\$104.8 million) allocated to the R&D of our pre-clinical stage drug candidates; and
- approximately 10% of the net proceeds (approximately HK\$174.7 million) allocated to our working capital and general corporate purposes.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$270.7 million for 13,852,000 additional Offer Shares to be sold and transferred upon the exercise of the Over-allotment Option.

For details of the use of proceeds, see the section headed “Future Plans and Use of Proceeds” in the Prospectus.



## APPLICATIONS UNDER THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been very significantly over-subscribed. A total of 194,271 valid applications have been received pursuant to the Hong Kong Public Offering on **WHITE** and **YELLOW** Application Forms and through giving **electronic application instructions** to HKSCC via CCASS and under the **White Form eIPO** service ([www.eipo.com.hk](http://www.eipo.com.hk)) for a total of 5,091,437,500 Hong Kong Offer Shares, representing approximately 551.32 times of the total number of 9,235,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.

Of the 194,271 valid applications on **WHITE** and **YELLOW** Application Forms or to the designated **White Form eIPO** Service Provider through **White Form eIPO** service at [www.eipo.com.hk](http://www.eipo.com.hk) and by **electronic application instructions** given to HKSCC for a total of 5,091,437,500 Hong Kong Offer Shares, a total of 189,527 valid applications in respect of a total of 1,595,925,000 Hong Kong Offer Shares were for Hong Kong Offer Shares with an aggregate subscription amount based on the Offer Price of HK\$20.15 per Offer Share (excluding the brokerage, SFC transaction levy and the Stock Exchange trading fee) of HK\$5 million or less (representing approximately 345.63 times of the 4,617,500 Hong Kong Offer Shares initially comprised in pool A), and a total of 4,744 valid applications in respect of a total of 3,495,512,500 Hong Kong Offer Shares were for Hong Kong Offer Shares with an aggregate subscription amount based on the Offer Price of HK\$20.15 per Offer Share (excluding the brokerage, SFC transaction levy and the Stock Exchange trading fee) of more than HK\$5 million (representing approximately 757.01 times of the 4,617,500 Hong Kong Offer Shares initially comprised in pool B). The total number of successful applicants under the Hong Kong Public Offering is 44,242.

No application has been rejected due to invalid application which is not completed in accordance with the instructions set out in the Application Forms. 415 multiple applications or suspected multiple applications have been identified and rejected. 2 applications have been rejected due to bounced checks. No applications for more than 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering (being 4,617,500 Shares) have been identified.

As the over-subscription in the Hong Kong Public Offering is more than 100 times, the reallocation procedures as described in the section headed “Structure of the Global Offering – The Hong Kong Public Offering – Reallocation” in the Prospectus have been applied. A total number of 36,939,000 Offer Shares have been reallocated to the Hong Kong Public Offering from the International Offering. As a result of such reallocation, the final number of Offer Shares available under the Hong Kong Public Offering has been increased to 46,174,000 Offer Shares, representing approximately 50% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

The Hong Kong Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed “Basis of allotment under the Hong Kong Public Offering” below.

## INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering have been significantly over-subscribed, which, based on orders received from the International Underwriters, represents more than 8 times the total number of Offer Shares initially available under the International Offering. Taking into account the reallocation of 36,939,000 Offer Shares from the International Offering to the Hong Kong Public Offering, the final number of Offer Shares under the International Offering is 46,173,500 Shares, representing approximately 50% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 13,852,000 Offer Shares under the International Offering. A total number of 175 places have been allocated Offer Shares under the International Offering.

## CORNERSTONE INVESTORS

Based on the Offer Price of HK\$20.15 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), pursuant to the cornerstone investment agreements with the Cornerstone Investors as disclosed in the section headed “Cornerstone Investors” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors is determined as set out below:

	Number of Offer Shares subscribed for (rounded down to nearest whole board lot of 500 Shares)	Approximately % of total number of Offer Shares		Approximately % of total Shares in issue immediately following the completion of Global Offering	
		Assuming the Over-allotment Option is not exercised	Assuming the Over-allotment Option is exercised in full	Assuming the Over-allotment Option is not exercised	Assuming the Over-allotment Option is exercised in full
Zhuhai Gree Financial Investment Management Co. Ltd (珠海格力金融投資管理有限公司)	37,696,500	40.82%	35.50%	10.21%	9.84%
Foresight Orient Global Superior Choice SPC	1,923,000	2.08%	1.81%	0.52%	0.50%
Highlight Medical Limited	1,923,000	2.08%	1.81%	0.52%	0.50%
Cherry Cheeks HK Limited	2,692,500	2.92%	2.54%	0.73%	0.70%
<b>Total</b>	<b>44,235,000</b>	<b>47.90%</b>	<b>41.65%</b>	<b>11.98%</b>	<b>11.54%</b>

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver from strict compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 5(2) of the Placing Guidelines, to permit (i) Highlight Medical Limited and (ii) Cherry Cheeks HK Limited (each an existing shareholder of the Company) to subscribe for Offer Shares as Cornerstone Investors in the Global Offering. Please refer to the section headed “Waivers from Compliance with the Listing Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus.

To the best knowledge of the Directors, (i) save as being our existing Shareholders, each of Highlight Medical Limited and Cherry Cheeks HK Limited is an independent third party and is not our connected person (as defined in the Listing Rule), (ii) is not accustomed to take instructions from the Company, the Directors, chief executives of the Company, substantial Shareholders, other existing Shareholders or any of its subsidiaries or their respective close associates; (iii) none of the subscription of the relevant Offer Shares by each of them is financed by the Company, the Directors, chief executives of the Company, substantial Shareholders, other existing Shareholders or any of its subsidiaries or their respective close associates.

The Cornerstone Placing will form part of the International Offering, and the Cornerstone Investors will not acquire any Offer Shares under the Global Offering other than pursuant to the cornerstone investment agreements. The Offer Shares to be subscribed by the Cornerstone Investors will rank *pari passu* in all respects with the other fully paid Offer Shares in issue and will not be counted towards the public float of the Company pursuant to Rule 18A.07 of the Listing Rules. Immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), none of the Cornerstone Investors will have any Board representation in the Company or, save for Zhuhai Gree Financial Investment Management Co., Ltd, become a substantial Shareholder. The Cornerstone Investors do not have any preferential rights in the cornerstone investment agreements compared with other public Shareholders.

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six months following the Listing Date (the “**Lock-up Period**”), effect any disposal (as defined in the respective cornerstone investment agreement) of any of the Offer Shares subscribed for it pursuant to the relevant cornerstone investment agreements, save for certain limited circumstances, such as transfer to a wholly-owned subsidiary of such Cornerstone Investor, provided that among other things, such wholly-owned subsidiary undertakes in writing that such wholly-owned subsidiary be bound by the Cornerstone Investor’s obligation under the relevant cornerstone investment agreement, including the Lock-up Period restriction.

Please refer to the section headed “Cornerstone Investment” in the Prospectus for further details relating to the Cornerstone Investors.

## PLACING OF OFFER SHARES WITH CONSENT UNDER THE PLACING GUIDELINES

Certain Offer Shares were placed to connected clients of Huatai Financial Holding (Hong Kong) Limited (the Sole Sponsor, a Joint Global Coordinator, and a Joint Bookrunner) and UBS AG Hong Kong Branch (a Joint Global Coordinator and a Joint Bookrunner) (the “**Connected Underwriters**”) within the meaning of the Placing Guidelines, details of which are set out below:

Connected Underwriter	Placee	Number of Offer Shares placed	Approximate % of total number of Offer Shares		Approximate % of total Shares in issue immediately following the completion of the Global Offering		Relationship with the Connected Underwriter(s)
			Assuming the Over-allotment Option is not exercised	Assuming the Over-allotment Option is exercised in full	Assuming the Over-allotment Option is not exercised	Assuming the Over-allotment Option is exercised in full	
Huatai Financial Holdings (Hong Kong) Limited	CSOP	155,000	0.17%	0.15%	0.04%	0.04%	CSOP is a member of the same group of companies as Huatai Financial Holdings (Hong Kong) Limited.
	Huatai Capital	25,000	0.03%	0.02%	0.01%	0.01%	Huatai Capital is a member of the same group of companies as Huatai Financial Holding (Hong Kong) Limited.
UBS AG Hong Kong Branch	UBS AM (Singapore)	400,000	0.43%	0.38%	0.11%	0.10%	UBS AM (Singapore) is a member of the same group of companies as UBS AG Hong Kong Branch.
		<u>580,000</u>	<u>0.63%</u>	<u>0.55%</u>	<u>0.16%</u>	<u>0.15%</u>	

### CSOP

155,000 Offer Shares, representing approximately 0.17% of the Shares in issue immediately upon the completion of the Global Offering (before the exercise of the Over-allotment Option), were placed to CSOP (in its capacity a discretionary fund manager managing assets on behalf of its underlying clients), which is a connected client of Huatai Financial Holdings (Hong Kong) Limited within the meaning of the Placing Guidelines. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to CSOP. To the best of CSOP’s knowledge, after making all reasonable inquiries, each of CSOP’s ultimate clients is an independent third party, and is not a connected person (as defined in the Listing Rules) of the Company or their respective associates (as defined in the Listing Rules) and is in compliance with all the conditions under the consent granted by the Stock Exchange.

## **Huatai Capital**

25,000 Offer Shares, representing approximately 0.03% of the Shares in issue immediately upon the completion of the Global Offering (before the exercise of the Over-allotment Option), were placed to Huatai Capital, which is a connected client of Huatai Financial Holdings (Hong Kong) Limited within the meaning of the Placing Guidelines. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to Huatai Capital. To the best of Huatai Capital's knowledge, after making all reasonable inquiries, each of Huatai Capital's ultimate clients is an independent third party, and is not a connected person (as defined in the Listing Rules) of the Company or their respective associates (as defined in the Listing Rules) and is in compliance with all the conditions under the consent granted by the Stock Exchange.

## **UBS AM (Singapore)**

400,000 Offer Shares, representing approximately 0.43% of the Shares in issue immediately upon the completion of the Global Offering (before the exercise of the Over-allotment Option and), were placed to UBS AM (Singapore) (in its capacity as a discretionary fund manager managing assets on behalf of its underlying clients), which is a connected client of UBS AG Hong Kong Branch within the meaning of the Placing Guidelines. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to UBS AM (Singapore). To the best of UBS AM (Singapore)'s knowledge, after making all reasonable inquiries, each of the UBS AM (Singapore)'s ultimate clients is an independent third party, and is not a connected person (as defined in the Listing Rules) of the Company or their respective associates (as defined in the Listing Rules) and is in compliance with all the conditions under the consent granted by the Stock Exchange.

Save as disclosed in the paragraphs headed "Cornerstone Investors", and "Placing of Offer Shares with consent under the Placing Guidelines" in this announcement, and pursuant to the cornerstone investment agreements, no Offer Shares placed by or through the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers and the Underwriters under the Global Offering have been placed with any core connected person (as defined in the Listing Rules) of the Company or any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees. The Directors confirm that save for Zhuhai Gree Financial Investment Management Co. Ltd. no placee, individually, will hold more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering (assuming the Over-allotment Option is not exercised).

The Directors confirm that, to the best of their knowledge, save as the Cornerstone Investors which are existing Shareholders namely, Highlight Medical Limited and Cherry Cheeks HK Limited (please refer to the paragraph headed "Cornerstone Investors"), none of the Offer Shares subscribed by the placees and the public has been financed directly or indirectly by any of the Directors, chief executives of the Company, substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates, and none of the placees and the public who has subscribed for the Offer Shares is accustomed to taking instructions from any of the Directors, chief executives of the Company, the substantial Shareholders, existing Shareholders or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in his/her/its name or otherwise held by him/her/it.

## OVER-ALLOTMENT OPTION

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators on behalf of the International Underwriters, at any time from the Listing Date until Sunday, 14 June 2020, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to an aggregate of 13,852,000 additional Shares, representing approximately 15% of the Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any. There has been an over-allocation of 13,852,000 Shares in the International Offering which will be from Shares to be borrowed under the Stock Borrowing Agreement between KT International and the Stabilising Manager. Such borrowed Shares will be covered by (i) exercising the Over-allotment Option in full or in part, (ii) by making purchases by the Stabilising Manager (or any person acting for it) in the secondary market at prices that do not exceed the offer price, or (iii) by a combination of these means. If the Over-allotment Option is exercised, an announcement will be made in accordance with the Listing Rules. As at the date of this announcement, the Over-allotment Option has not been exercised.

## LOCK-UP UNDERTAKINGS

Each of the Company, the Controlling Shareholders, the existing Shareholders (comprising KT International, KG Development and the Pre-IPO investors) and the Cornerstone Investors has given certain undertakings in relation to the issue or disposal of Shares (the “**Lock-up Undertakings**”). The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of Shares held in the Company subject to the Lock-up Undertakings upon the Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings upon the Listing <sup>(Note 3)</sup>	Last day subject to the Lock-up Undertakings
<i>The Company (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)</i>	N/A	N/A	21 November 2020 <sup>(Note 1)</sup>
<i><b>The Controlling Shareholders</b> (subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)</i>			
Dr. Tong	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>
Dr. Guo	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>
KT International	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>
KG Development	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>



Name	Number of Shares held in the Company subject to the Lock-up Undertakings upon the Listing	Percentage of shareholding in the Company subject to the Lock-up Undertakings upon the Listing <sup>(Note 3)</sup>	Last day subject to the Lock-up Undertakings
<b><i>The existing Shareholders comprising KT International, KG Development and the Pre-IPO Investors</i></b>			
<i>(subject to lock-up obligations pursuant to the Shareholders Agreement)</i>			
KT International	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>
KG Development	51,037,270	13.82%	21 November 2020 <sup>(Note 2)</sup>
Real Able Limited	28,000,000	7.58%	21 November 2020 <sup>(Note 2)</sup>
Kiya	23,613,590	6.39%	21 November 2020 <sup>(Note 2)</sup>
Highlight Medical	20,007,770	6.01%	21 November 2020 <sup>(Note 2)</sup>
Sungent Venture Limited	19,307,000	5.23%	21 November 2020 <sup>(Note 2)</sup>
Origin VC	18,628,240	5.04%	21 November 2020 <sup>(Note 2)</sup>
Genius Found Limited	7,862,520	2.13%	21 November 2020 <sup>(Note 2)</sup>
Cherry Cheeks	7,058,150	2.74%	21 November 2020 <sup>(Note 2)</sup>
Shanghai FTZ Fund	6,265,830	1.70%	21 November 2020 <sup>(Note 2)</sup>
Orient Tengcong Limited	5,616,080	1.52%	21 November 2020 <sup>(Note 2)</sup>
Bexin Capital Limited	4,492,860	1.22%	21 November 2020 <sup>(Note 2)</sup>
Zhuhai Huajin	4,177,220	1.13%	21 November 2020 <sup>(Note 2)</sup>
CCBI Tech Venture	3,655,070	0.99%	21 November 2020 <sup>(Note 2)</sup>
Board Resources Global Biomedical II Ltd	3,369,650	0.91%	21 November 2020 <sup>(Note 2)</sup>
Xuanling Biomedica Limited	2,786,120	0.75%	21 November 2020 <sup>(Note 2)</sup>
KT Joinne Capital Limited	2,752,850	0.75%	21 November 2020 <sup>(Note 2)</sup>
Beijing Yirongchuang	2,700,000	0.73%	21 November 2020 <sup>(Note 2)</sup>
Guangzhou Chengfa	2,610,770	0.71%	21 November 2020 <sup>(Note 2)</sup>
Taihong Pharma Limited	2,289,560	0.62%	21 November 2020 <sup>(Note 2)</sup>
CCB International Overseas Limited	2,240,000	0.61%	21 November 2020 <sup>(Note 2)</sup>
Chengdu Hi-Tech FTZ	1,540,350	0.42%	21 November 2020 <sup>(Note 2)</sup>
Catreed Biomedica, Ltd	1,033,560	0.28%	21 November 2020 <sup>(Note 2)</sup>
Modest Champion Limited	1,129,650	0.31%	21 November 2020 <sup>(Note 2)</sup>
Highsino Group Limited	1,123,220	0.30%	21 November 2020 <sup>(Note 2)</sup>
Cheung Ming Ming	783,230	0.21%	21 November 2020 <sup>(Note 2)</sup>
Minghai Biomedica Limited	674,060	0.18%	21 November 2020 <sup>(Note 2)</sup>
Sinvas Asset	522,150	0.14%	21 November 2020 <sup>(Note 2)</sup>
Yahe Biomedica Investment Limited	449,370	0.12%	21 November 2020 <sup>(Note 2)</sup>
Xinlemei Biomedica Limited	224,690	0.06%	21 November 2020 <sup>(Note 2)</sup>
Beijing Yicheng Hongtai	54,000	0.01%	21 November 2020 <sup>(Note 2)</sup>

<b>Name</b>	<b>Number of Shares held in the Company subject to the Lock-up Undertakings upon the Listing</b>	<b>Percentage of shareholding in the Company subject to the Lock-up Undertakings upon the Listing <sup>(Note 3)</sup></b>	<b>Last day subject to the Lock-up Undertakings</b>
<b><i>Cornerstone Investors (subject to lock-up obligations pursuant to the cornerstone investment agreements)</i></b>			
Zhuhai Gree Financial Investment Management Co. Ltd (珠海格力金融投資管理有限公司)	37,696,500	10.21%	21 November 2020 <sup>(Note 2)</sup>
Foresight Orient Global Superior Choice SPC	1,923,000	0.52%	21 November 2020 <sup>(Note 2)</sup>
Highlight Medical Limited	1,923,000	0.52%	21 November 2020 <sup>(Note 2)</sup>
Cherry Cheeks HK Limited	2,692,500	0.73%	21 November 2020 <sup>(Note 2)</sup>

*Notes:*

1. *The Company may issue Shares without any lock-up obligations after the indicated date.*
2. *The Controlling Shareholders, the existing Shareholders (comprising KT International, KG Development and the Pre-IPO investors) and the Cornerstone Investors may dispose of or transfer Shares without any lock-up obligation after the indicated date.*
3. *Assuming the Over-allotment Option is not exercised.*

## BASIS OF ALLOTMENT UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed “Structure of the Global Offering – Conditions of the Global Offering” in the Prospectus, valid applications made by the public on **WHITE** and **YELLOW** Application Forms, to the **White Form eIPO** Service Provider under the **White Form eIPO** service and through giving **electronic application instructions** to HKSCC via CCASS will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
<b>POOL A</b>			
500	88,762	8,876 out of 88,762 to receive 500 Shares	10.00%
1,000	13,804	1,408 out of 13,804 to receive 500 Shares	5.10%
1,500	5,089	552 out of 5,089 to receive 500 Shares	3.62%
2,000	9,391	1,052 out of 9,391 to receive 500 Shares	2.80%
2,500	3,252	373 out of 3,252 to receive 500 Shares	2.29%
3,000	3,673	463 out of 3,673 to receive 500 Shares	2.10%
3,500	1,249	166 out of 1,249 to receive 500 Shares	1.90%
4,000	1,917	268 out of 1,917 to receive 500 Shares	1.75%
4,500	2,032	302 out of 2,032 to receive 500 Shares	1.65%
5,000	8,974	1,436 out of 8,974 to receive 500 Shares	1.60%
6,000	3,788	705 out of 3,788 to receive 500 Shares	1.55%
7,000	4,577	961 out of 4,577 to receive 500 Shares	1.50%
8,000	2,622	608 out of 2,622 to receive 500 Shares	1.45%
9,000	4,946	1,246 out of 4,946 to receive 500 Shares	1.40%
10,000	10,509	2,837 out of 10,509 to receive 500 Shares	1.35%
15,000	4,907	1,914 out of 4,907 to receive 500 Shares	1.30%
20,000	4,270	2,135 out of 4,270 to receive 500 Shares	1.25%
25,000	2,376	1,473 out of 2,376 to receive 500 Shares	1.24%
30,000	1,976	1,458 out of 1,976 to receive 500 Shares	1.23%
35,000	812	693 out of 812 to receive 500 Shares	1.22%
40,000	912	883 out of 912 to receive 500 Shares	1.21%
45,000	564	500 Shares	1.11%
50,000	2,658	500 Shares plus 266 out of 2,658 to receive additional 500 Shares	1.10%
55,000	360	500 Shares plus 72 out of 360 to receive additional 500 Shares	1.09%
60,000	578	500 Shares plus 171 out of 578 to receive additional 500 Shares	1.08%
65,000	204	500 Shares plus 80 out of 204 to receive additional 500 Shares	1.07%
70,000	418	500 Shares plus 202 out of 418 to receive additional 500 Shares	1.06%
75,000	372	500 Shares plus 214 out of 372 to receive additional 500 Shares	1.05%
80,000	374	500 Shares plus 248 out of 374 to receive additional 500 Shares	1.04%
85,000	123	500 Shares plus 92 out of 123 to receive additional 500 Shares	1.03%
90,000	180	500 Shares plus 150 out of 180 to receive additional 500 Shares	1.02%
95,000	113	500 Shares plus 104 out of 113 to receive additional 500 Shares	1.01%
100,000	2,413	1,000 Shares	1.00%
200,000	1,332	1,500 Shares	0.75%

189,527

<b>NO. OF SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR</b>
<b>POOL B</b>			
300,000	2,818	2,500 Shares plus 659 out of 2,818 to receive additional 500 Shares	0.87%
400,000	344	3,000 Shares	0.75%
500,000	381	3,500 Shares	0.70%
600,000	115	4,000 Shares	0.67%
700,000	124	4,500 Shares	0.64%
800,000	92	5,000 Shares	0.63%
900,000	38	5,500 Shares	0.61%
1,000,000	321	6,000 Shares	0.60%
2,000,000	157	11,500 Shares	0.58%
3,000,000	113	17,000 Shares	0.57%
4,000,000	46	22,500 Shares	0.56%
4,617,500	195	25,500 Shares	0.55%
	<u>4,744</u>		

The final number of Offer Shares comprised in the Hong Kong Public Offering is 46,174,000 Offer Shares, representing approximately 50% of the total number of the Offer Shares initially available under the Global Offering. The final number of Offer Shares comprised in the International Offering is 46,173,500 Offer Shares, representing approximately 50% of the total number of the Offer Shares initially available under the Global Offering.

## RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for under **WHITE** and **YELLOW** Application Forms and by giving **electronic application instructions** to HKSCC or through the designated **White Form eIPO** service, including the Hong Kong identity card numbers, passport numbers or Hong Kong business registration numbers of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:

- in this announcement posted on the Company's website at [www.kintor.com.cn](http://www.kintor.com.cn) and the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) by no later than 9:00 a.m. on Thursday, 21 May 2020;
- from the designated results of allocations website at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <http://www.eipo.com.hk/en/Allotment>; Chinese <http://www.eipo.com.hk/zh-hk/Allotment>) with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Thursday, 21 May 2020 to 12:00 midnight on Wednesday, 27 May 2020;
- by telephone enquiry line by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. from Thursday, 21 May 2020 to Friday, 22 May 2020 and from Monday, 25 May 2020 to Tuesday, 26 May 2020;
- in the special allocation results booklets which will be available for inspection during opening hours from Thursday, 21 May 2020 to Monday, 25 May 2020 at all the designated branches as set out below:

### Bank of China (Hong Kong) Limited

	Branch	Address
<b>Hong Kong Island</b>	Central District (Wing On House) Branch	B/F-2/F, Wing On House 71 Des Voeux Road Central Central
	North Point (King's Centre) Branch	193-209 King's Road North Point
<b>Kowloon</b>	Telford Plaza Branch	Shop Unit P2-P7, Telford Plaza No. 33 Wai Yip Street Kowloon Bay
	Tsim Sha Tsui East Branch	Shop 3, LG/F, Hilton Towers 96 Granville Road Tsim Sha Tsui East
<b>New Territories</b>	Kau Yuk Road Branch	18-24 Kau Yuk Road, Yuen Long, New Territories

## Standard Chartered Bank (Hong Kong) Limited

	<b>Branch</b>	<b>Address</b>
<b>Hong Kong Island</b>	Central Branch	G/F, 1/F, 2/F and 27/F Two Chinachem Central 26 Des Voeux Road Central
	Causeway Bay Branch	G/F to 2/F Yee Wah Mansion 38-40A Yee Wo Street Causeway Bay
<b>Kowloon</b>	Mongkok Branch	Shop B, G/F, 1/F & 2/F 617-623 Nathan Road Mongkok
	Tsimshatsui Branch	Shop G30 & B117-23, G/F Mira Place One 132 Nathan Road Tsim Sha Tsui
<b>New Territories</b>	Tsuen Wan Branch	Shop C, G/F & 1/F Jade Plaza 298 Sha Tsui Road Tsuen Wan

The level of indication of interests in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will also be published on Thursday, 21 May 2020 in the Newspapers and on the Company's website at [www.kintor.com.cn](http://www.kintor.com.cn) and the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).



## SHAREHOLDING CONCENTRATION ANALYSIS

We set out a summary of allotment results under the Global Offering:

- Top 1, 5, 10 and 25 of the Shareholders out of the International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Shareholders	Subscription	Aggregate number of Shares held upon Listing	Subscription as % of the International Offer Shares (as adjusted after reallocation and assuming no exercise of Over-allotment Option)	Subscription as % of the International Offer Shares (as adjusted after reallocation and assuming full exercise of Over-allotment Option)	Subscription as % of total Offer Shares (assuming no exercise of Over-allotment Option)	Subscription as % of total Offer Shares (assuming full exercise of Over-allotment Option)	% of total share capital in issue upon Listing (assuming no exercise of Over-allotment Option)	% of total share capital in issue upon Listing (assuming full exercise of Over-allotment Option)
Top 1	0	51,037,270	0.00%	0.00%	0.00%	0.00%	13.82%	13.32%
Top 5	37,696,500	191,384,630	45.36%	38.88%	40.82%	35.50%	51.81%	49.94%
Top 10	42,312,000	268,863,810	50.91%	43.64%	45.82%	39.84%	72.79%	70.16%
Top 25	46,235,000	317,283,170	55.63%	47.68%	50.07%	43.54%	85.89%	82.79%

- Top 1, 5, 10 and 25 of the places out of the International Offer Shares, total Offer Shares and total issued share capital of the Company upon Listing:

Places	Subscription	Aggregate number of Shares held upon Listing	Subscription as % of the International Offer Shares (as adjusted after reallocation and assuming no exercise of Over-allotment Option)	Subscription as % of the International Offer Shares (as adjusted after reallocation and assuming full exercise of Over-allotment Option)	Subscription as % of total Offer Shares (assuming no exercise of Over-allotment Option)	Subscription as % of total Offer Shares (assuming full exercise of Over-allotment Option)	% of total share capital in issue upon Listing (assuming no exercise of Over-allotment Option)	% of total share capital in issue upon Listing (assuming full exercise of Over-allotment Option)
Top 1	37,696,500	37,696,500	45.36%	38.88%	40.82%	35.50%	10.21%	9.84%
Top 5	46,235,000	73,300,920	55.63%	47.68%	50.07%	43.54%	19.84%	19.13%
Top 10	50,910,000	77,975,920	61.25%	52.50%	55.13%	47.94%	21.11%	20.35%
Top 25	55,952,000	83,017,920	67.32%	57.70%	60.59%	52.69%	22.47%	21.66%